As the new year begins, clinical laboratory managers must proactively anticipate the emerging trends that will redefine the healthcare landscape in 2024. One of the key focal points revolves around integrating emerging technologies (ETs) into laboratory medicine, a trajectory set to profoundly transform diagnostics and prevention. These ETs encompass a plethora of tools across clinical, analytical, operational, and financial domains and are poised to revolutionize routine clinical practice.¹ However, successfully integrating these innovations requires a systematic approach that utilizes eight pivotal tools to streamline the implementation life cycle.¹

The paradigm shift in laboratory medicine is further underscored by advancements in personalized medicine and enhanced molecular diagnostics.^2,3 Tailoring treatments based on an individual’s genetic makeup and lifestyle is at the forefront, promising more precise diagnoses, and treatments. Notably, proteomic and lipidomic panels, augmented by machine learning-based algorithms, are poised to reveal an individual’s susceptibility to future incidents or recurrent atherosclerotic cardiovascular disease (ASCVD) risk.² When combined with genetic predisposition and the observed ASCVD phenotype, these advancements unlock a deeper understanding of the multifaceted causes that underpin an individual’s risk profile.

Furthermore, relentlessly pursuing point-of-care testing and integrating nanotechnology into diagnostics herald a future in which rapid, portable diagnostic tools will revolutionize patient care.⁴ The potential for early disease detection, coupled with the agility afforded by POC testing, offers a glimpse into a future where diagnostic accuracy meets expeditious decision-making at the point of care.

However, true metamorphosis lies in the convergence of artificial intelligence (AI), hyperautomation, generative AI, and the unfolding metaverse. Laboratories are on the brink of a revolution driven by increased automation that minimizes human errors and enhances sample processing, analysis, and data interpretation.^5,6 AI technologies, including machine learning algorithms, are set to revolutionize clinical decision-making. This is demonstrated through the development of novel risk algorithms and the diagnosis of cardiac diseases, such as myocardial infarction, coronary artery disease, and atrial fibrillation.^7,8

However, the transformative power of AI introduces complex challenges, particularly concerning patient privacy, opaque corporate interests, and the secure integration of AI into healthcare settings. To navigate these challenges and ensure the ethical and responsible adoption of AI in medicine, collaboration among health institutions, technology companies, and regulatory bodies is crucial.⁷

The emergence of the metaverse is a novel avenue for laboratory medicine, promising augmented services, enhanced user experience, and personalized care. Scientific societies and multidisciplinary teams in laboratory medicine must anticipate the integration of the metaverse, and embrace the potential while addressing inherent challenges.⁹

Crucially, among these transformative waves, seamlessly integrating and connecting laboratory data with electronic health records remains pivotal.¹⁰ Standardized data formats, such as Fast healthcare interoperability resources, serve as beacons for scalable and needs-driven data modeling in clinical settings.

In conclusion, the year 2024 marks an era where the convergence of ETs, AI, hyperautomation, and the metaverse propels laboratory medicine into uncharted territories (Figure 1). The strategic integration of these trends requires a concerted effort, combining innovation with responsible implementation. Laboratory managers are at the helm of this transformative journey, steering the healthcare industry toward a future where precision, efficiency, and patient-centricity converge to redefine the art and science of diagnostics and patient care.

Authorship Contributions: Concept- D.G.; Analysis or Interpretation- T.K.Ö.; Critical Review- D.G., T.K.Ö.

Conflict of Interest: No conflict of interest was declared by the authors.

REFERENCES

1. Greaves R, Kricka L, Gruson D, et al. Toolkit for emerging technologies in laboratory medicine. Clin Chem Lab Med [Internet]. 2023;61.
2. Nurmohamed NS, Kraaijenhof JM, Mayr M, et al. Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction. Eur Heart J [Internet]. 2023;44:1594-607.
3. Aboumsallem JP, Shi C, De Wit S, Markousis-Mavrogenis G, Bracun V, Eijgenraam TR, et al. Multi-omics analyses identify molecular signatures with prognostic values in different heart failure aetiologies. J Mol Cell Cardiol [Internet]. 2023;175:13-28.
4. King KR, Grazette LP, Paltoo DN, et al. Point-of-Care Technologies for Precision Cardiovascular Care and Clinical Research: National Heart, Lung, and Blood Institute Working Group. JACC Basic Transl Sci [Internet]. 2016;1:73.
5. Gruson D, Magalhaes T, Ruszanov A, et al. Perspectives from a joint IFCC-EHMA session Hyperautomation in Healthcare: perspectives from a joint IFCC-EHMA session. [cited 2023 Dec 30];
6. Toma A, Senkaiahliyan S, Lawler PR, Rubin B, Wang B. Generative AI could revolutionize health care-but not if control is ceded to big tech. Nature [Internet]. 2023;624:36-8.
7. Gruson D, Gruson D, Macq B. The Next Clinical Decision Frontier: How to Efficiently and Safely Combine Machine Learning and Human Expertise. Clin Chem [Internet]. 2023 Nov 29 [cited 2023 Dec 30];
8. Altay S, Hayıroğlu Mİ. The Role of Artificial Intelligence in Coronary Artery Disease and Atrial Fibrillation. Balkan Med J [Internet]. 2023;40:151.
9. Gruson D, Greaves R, Dabla P, Bernardini S, Gouget B, Öz TK. A new door to a different world: opportunities from the metaverse and the raise of meta-medical laboratories. Clin Chem Lab Med [Internet]. 2023;61:1567-71.
10. Williams E, Kienast M, Medawar E, et al. A Standardized Clinical Data Harmonization Pipeline for Scalable AI Application Deployment (FHIR-DHP): Validation and Usability Study. JMIR Med Inform [Internet]. 2023;11.